# OnCo record braf-v600e (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/braf-v600e/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "braf-v600e" ;
  schema:name "BRAF V600E (and V600K)"@en ;
  schema:alternateName "BRAF V600E"@en, "V600E"@en, "BRAF V600"@en, "BRAF V600K"@en, "BRAF-mutant"@en, "BRAF class I mutation"@en, "BRAF V600E-mutant"@en ;
  schema:description "V600E is the BRAF change that drives half of melanomas and many thyroid, bowel, lung and brain tumours. BRAF plus MEK inhibitors are approved for it in melanoma, lung, thyroid and, tumour-agnostically, any solid tumour; in bowel cancer it is treated with encorafenib and cetuximab."@en ;
  schema:url <https://onco.cc/biomarkers/braf-v600e/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c> ;
  onco:tag "biomarker", "braf" ;
  onco:related <https://onco.cc/biomarkers/braf-class-ii-iii/>, <https://onco.cc/biomarkers/braf-fusion/>, <https://onco.cc/biomarkers/kras-g12c/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/anaplastic-thyroid-cancer/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/therascreen-cdx/> ;
  onco:terms <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/tumour-agnostic/> .